移植片対宿主病治療市場：疾患タイプ、製品タイプ、エンドユーザー別-2025-2030年の世界予測

移植片対宿主病治療市場は、2023年に18億7,000万米ドルと評価され、2024年には20億6,000万米ドルに達すると予測され、CAGR 10.45％で成長し、2030年には37億6,000万米ドルに達すると予測されています。

移植片対宿主病（GVHD）治療には通常、ドナー由来の免疫細胞が移植後にレシピエントの体組織を攻撃する際の免疫反応を減弱させることを目的とした医薬品や治療法が含まれます。これらの治療の必要性は、特に骨髄移植や幹細胞移植の患者において、移植の成功や患者の生存を保証する上で重要な役割を果たすことによって強調されています。用途は、急性および慢性のGVHD症状の両方を対象とした、副腎皮質ステロイド、TNF阻害剤、新規生物学的製剤のような医薬品の範囲に及ぶ。最終用途は、複雑な治療レジメンに対応できる熟練したヘルスケア専門家に支えられた病院や専門移植センターが中心です。市場は主に、移植手術の増加、高度な診断、新規免疫抑制療法の研究開発の増加によって牽引されています。ゲノム技術やバイオマーカー探索の進歩により、個別化医療や精密免疫療法が注目され、オーダーメイドの治療が可能になります。バイオテクノロジー企業間の戦略的提携、医療資金の増加、規制当局の支援により、製品の革新と市場への参入が促進されます。

課題としては、先進的治療法の高コスト、規制上のハードル、二次感染や悪性腫瘍の原因となる既存の免疫抑制剤に伴う副作用などが挙げられます。さらに、疾患のメカニズムが複雑であるため、普遍的に有効な治療法を開発する上で大きな障壁となっています。GVHD発症の予測可能性や症状のばらつきが限られているため、より適応的な治療アプローチが必要となり、臨床結果と患者のニーズを一致させることが難しくなっています。

革新的な研究分野には、免疫反応を正確に調節するためのCRISPRのような遺伝子編集技術、微生物ベースの治療法の開発、CAR-TやTregを用いた細胞治療の強化などがあります。市場は本来ダイナミックなものであり、アンメットニーズに効率的に対応するため、個別化された技術主導のアプローチを採用する方向に引き寄せられます。したがって、企業は戦略的パートナーシップ、患者中心の臨床試験、技術統合に注力し、課題を克服しながら効果的な製品開発を推進することで、潜在的な事業成長機会を得ることができます。

市場力学：急速に進化する移植片対宿主病治療市場における主要市場インサイトの解明

移植片対宿主病治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 航空貨物収入とトン数の増加による、大型貨物や重量貨物の増加
  • 同種移植件数の増加
  • 同種造血幹細胞移植を受ける患者数の増加
• 市場抑制要因
  • デジタル化による混乱と世界各地での貨物輸送のスピードアップ要求
  • 他の輸送手段との競合
  • 治療方法における臨床的進歩
• 市場機会
  • 新興市場における貨物サービスの成長
  • 新しい航空機技術とデジタル化における技術開発
• 市場の課題
  • 貿易摩擦と業界規制の強化

ポーターの5つの力移植片対宿主病治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：移植片対宿主病治療市場における外部からの影響の把握

外部マクロ環境要因は、移植片対宿主病治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析移植片対宿主病治療市場における競合情勢の把握

移植片対宿主病治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス移植片対宿主病治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、移植片対宿主病治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨移植片対宿主病治療市場における成功への道筋を描く

移植片対宿主病治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 航空貨物収入と積載量の増加により、かさばる重量貨物の需要が増加
    • 同種移植の増加
    • 同種造血幹細胞移植を受ける患者数が増加
  • 抑制要因
    • デジタル化による混乱と、世界中の物品の移動を加速させる需要
    • 他の交通手段との競合
    • 治療手順の臨床的進歩
  • 機会
    • 新興市場における貨物サービスの成長
    • 新しい航空機技術とデジタル化の技術開発
  • 課題
    • 貿易摩擦と業界規制の強化
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 移植片対宿主病治療市場：疾患タイプ別

• 急性移植片対宿主病
• 慢性移植片対宿主病

第7章 移植片対宿主病治療市場：製品別

• コルチコステロイド
• モノクローナル抗体
• チロシンキナーゼ阻害剤

第8章 移植片対宿主病治療市場：エンドユーザー別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの移植片対宿主病治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の移植片対宿主病治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの移植片対宿主病治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• ElsaLys Biotech SA
• Johnson & Johnson Services, Inc.
• Mallinckrodt LLC
• Merck KGaA
• Mesoblast Limited
• Neovii Pharmaceuticals AG
• Novartis AG
• Ocugen, Inc.
• Pfizer Inc
• Pluristem Therapeutics Inc.
• Sanofi S.A.
• Soligenix, Inc.

LIST OF FIGURES

• FIGURE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GRAFT VERSUS HOST DISEASE TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ACUTE GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CHRONIC GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Graft Versus Host Disease Treatment Market was valued at USD 1.87 billion in 2023, expected to reach USD 2.06 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 3.76 billion by 2030.

Graft Versus Host Disease (GVHD) treatment typically encompasses pharmaceuticals and therapies aimed at attenuating the immune response when donor-derived immune cells attack the recipient's body tissue post-transplant. The necessity of these treatments is underscored by their critical role in ensuring transplant success and patient survival, especially in bone marrow and stem cell transplant patients. The application spans a range of pharmaceuticals like corticosteroids, TNF inhibitors, and novel biologics, targeting both acute and chronic GVHD manifestations. End-use scope prominently features hospitals and specialized transplant centers, backed by skilled healthcare professionals capable of handling complex treatment regimens. The market is primarily driven by rising transplantation procedures, advanced diagnostics, and increased R&D for novel immunosuppressive therapies. Emerging opportunities focus on personalized medicine and precision immunotherapies, aided by advances in genomic technologies and biomarker discovery, allowing tailored treatment pathways. Strategic collaboration between biotech firms, increased healthcare funding, and regulatory support enhances product innovation and market reach.

Challenges include the high cost of advanced therapies, regulatory hurdles, and side effects associated with existing immunosuppressants, which can contribute to secondary infections and malignancies. Additionally, the complexity of disease mechanisms poses significant barriers in developing universally efficacious treatments. Limited predictability of GVHD onset and variability of symptoms necessitate more adaptive therapeutic approaches, presenting hurdles in aligning clinical outcomes with patient needs.

Innovative research areas include gene editing technologies like CRISPR to modulate immune responses precisely, development of microbiome-based therapies, and enhanced cellular therapies using CAR-T and Tregs. The market, inherently dynamic, gravitates towards adopting personalized and technology-driven approaches to address unmet needs efficiently. Therefore, companies should focus on strategic partnerships, patient-centric trials, and technology integration to drive effective product development while navigating challenges, offering potential business growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graft Versus Host Disease Treatment Market

The Graft Versus Host Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
  • Growing number of allogeneic transplantations
  • Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
• Market Restraints
  • Disruption through digitization and demand to speed-up the movement of goods across the globe
  • Competition from other transport modes
  • Clinical advancements in the treatment procedure
• Market Opportunities
  • Growth of cargo services in emerging markets
  • Technological developments in new aircraft technologies and the digitization
• Market Challenges
  • Trade tensions and increasing industry regulation

Porter's Five Forces: A Strategic Tool for Navigating the Graft Versus Host Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graft Versus Host Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graft Versus Host Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graft Versus Host Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graft Versus Host Disease Treatment Market

A detailed market share analysis in the Graft Versus Host Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graft Versus Host Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graft Versus Host Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graft Versus Host Disease Treatment Market

A strategic analysis of the Graft Versus Host Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graft Versus Host Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, Johnson & Johnson Services, Inc., Mallinckrodt LLC, Merck KGaA, Mesoblast Limited, Neovii Pharmaceuticals AG, Novartis AG, Ocugen, Inc., Pfizer Inc, Pluristem Therapeutics Inc., Sanofi S.A., and Soligenix, Inc..

Market Segmentation & Coverage

This research report categorizes the Graft Versus Host Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Acute Graft Versus Host Disease and Chronic Graft Versus Host Disease.
• Based on Product, market is studied across Corticosteroids, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors.
• Based on End-User, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
    • 5.1.1.2. Growing number of allogeneic transplantations
    • 5.1.1.3. Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
  • 5.1.2. Restraints
    • 5.1.2.1. Disruption through digitization and demand to speed-up the movement of goods across the globe
    • 5.1.2.2. Competition from other transport modes
    • 5.1.2.3. Clinical advancements in the treatment procedure
  • 5.1.3. Opportunities
    • 5.1.3.1. Growth of cargo services in emerging markets
    • 5.1.3.2. Technological developments in new aircraft technologies and the digitization
  • 5.1.4. Challenges
    • 5.1.4.1. Trade tensions and increasing industry regulation
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Graft Versus Host Disease Treatment Market, by Disease Type

• 6.1. Introduction
• 6.2. Acute Graft Versus Host Disease
• 6.3. Chronic Graft Versus Host Disease

7. Graft Versus Host Disease Treatment Market, by Product

• 7.1. Introduction
• 7.2. Corticosteroids
• 7.3. Monoclonal Antibodies
• 7.4. Tyrosine Kinase Inhibitors

8. Graft Versus Host Disease Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Graft Versus Host Disease Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Graft Versus Host Disease Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Graft Versus Host Disease Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Astellas Pharma Inc.
• 3. Bristol-Myers Squibb Company
• 4. ElsaLys Biotech SA
• 5. Johnson & Johnson Services, Inc.
• 6. Mallinckrodt LLC
• 7. Merck KGaA
• 8. Mesoblast Limited
• 9. Neovii Pharmaceuticals AG
• 10. Novartis AG
• 11. Ocugen, Inc.
• 12. Pfizer Inc
• 13. Pluristem Therapeutics Inc.
• 14. Sanofi S.A.
• 15. Soligenix, Inc.